These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 17321463)

  • 21. Intestinal epithelial cells from inflammatory bowel disease patients preferentially stimulate CD4+ T cells to proliferate and secrete interferon-gamma.
    Dotan I; Allez M; Nakazawa A; Brimnes J; Schulder-Katz M; Mayer L
    Am J Physiol Gastrointest Liver Physiol; 2007 Jun; 292(6):G1630-40. PubMed ID: 17347451
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting the development and effector functions of TH17 cells.
    Ghilardi N; Ouyang W
    Semin Immunol; 2007 Dec; 19(6):383-93. PubMed ID: 18083530
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Commentary: the role of the IL-18 system and other members of the IL-1R/TLR superfamily in innate mucosal immunity and the pathogenesis of inflammatory bowel disease: friend or foe?
    Reuter BK; Pizarro TT
    Eur J Immunol; 2004 Sep; 34(9):2347-55. PubMed ID: 15307167
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The role and significance of the most important known cytokines in inflammatory bowel diseases].
    Vitális Z; Altorjay I; Udvardy M
    Orv Hetil; 1998 May; 139(21):1289-94. PubMed ID: 9632923
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regulation of gut inflammation and th17 cell response by interleukin-21.
    Fina D; Sarra M; Fantini MC; Rizzo A; Caruso R; Caprioli F; Stolfi C; Cardolini I; Dottori M; Boirivant M; Pallone F; Macdonald TT; Monteleone G
    Gastroenterology; 2008 Apr; 134(4):1038-48. PubMed ID: 18395085
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Negative regulation of IL-17 production by OX40/OX40L interaction.
    Li J; Li L; Shang X; Benson J; Merle Elloso M; Schantz A; Bracht M; Orlovsky Y; Sweet R
    Cell Immunol; 2008; 253(1-2):31-7. PubMed ID: 18501882
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune dysfunction in inflammatory bowel disease.
    Neuman MG
    Transl Res; 2007 Apr; 149(4):173-86. PubMed ID: 17383591
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The pathophysiologic rationale for biological therapies in inflammatory bowel disease.
    Gordon JN; Di Sabatino A; Macdonald TT
    Curr Opin Gastroenterol; 2005 Jul; 21(4):431-7. PubMed ID: 15930983
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical aspects of inflammatory bowel disease.
    Siegmund B; Zeitz M
    Eur J Immunol; 2009 Aug; 39(8):2026-30. PubMed ID: 19672897
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Validation of murine dextran sulfate sodium-induced colitis using four therapeutic agents for human inflammatory bowel disease.
    Melgar S; Karlsson L; Rehnström E; Karlsson A; Utkovic H; Jansson L; Michaëlsson E
    Int Immunopharmacol; 2008 Jun; 8(6):836-44. PubMed ID: 18442787
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Excess IL-12 but not IL-23 accompanies the inflammatory bowel disease associated with common variable immunodeficiency.
    Mannon PJ; Fuss IJ; Dill S; Friend J; Groden C; Hornung R; Yang Z; Yi C; Quezado M; Brown M; Strober W
    Gastroenterology; 2006 Sep; 131(3):748-56. PubMed ID: 16952544
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Growth hormone in inflammatory bowel disease.
    De Pascalis B; Bianchi A; Satta MA; Lupascu A; Mentella MC; Leo D; Fiore F; Fedeli P; Pontecorvi A; Pola P; Melina D; Gasbarrini A; De Marinis L; Armuzzi A
    Eur Rev Med Pharmacol Sci; 2006; 10(1):13-6. PubMed ID: 16494105
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neutralization of IL-17 by active vaccination inhibits IL-23-dependent autoimmune myocarditis.
    Sonderegger I; Röhn TA; Kurrer MO; Iezzi G; Zou Y; Kastelein RA; Bachmann MF; Kopf M
    Eur J Immunol; 2006 Nov; 36(11):2849-56. PubMed ID: 17039570
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Signaling for inflammation and repair in inflammatory bowel disease.
    Neuman MG
    Rom J Gastroenterol; 2004 Dec; 13(4):309-16. PubMed ID: 15624029
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic approaches in inflammatory bowel disease based on the immunopathogenesis.
    Siegmund B; Zeitz M
    Rocz Akad Med Bialymst; 2004; 49():22-30. PubMed ID: 15631310
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeted therapies in inflammatory bowel disease.
    Siegmund B
    Dig Dis; 2009; 27(4):465-9. PubMed ID: 19897961
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The IL-17/IL-23 axis of inflammation in cancer: friend or foe?
    Martin-Orozco N; Dong C
    Curr Opin Investig Drugs; 2009 Jun; 10(6):543-9. PubMed ID: 19513943
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New cytokine therapeutics for inflammatory bowel disease.
    Stokkers PC; Hommes DW
    Cytokine; 2004 Nov 21-Dec 7; 28(4-5):167-73. PubMed ID: 15588691
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interleukin-23 and TH17 cells in transplantation immunity: does 23+17 equal rejection?
    Chen Y; Wood KJ
    Transplantation; 2007 Nov; 84(9):1071-4. PubMed ID: 17998858
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease.
    Brand S
    Gut; 2009 Aug; 58(8):1152-67. PubMed ID: 19592695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.